{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:57Z","timestamp":1761871317712,"version":"build-2065373602"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.clml.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:06:04Z","timestamp":1543449964000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic Neutrophilic Leukemia: Current and Future Perspectives"],"prefix":"10.1016","volume":"19","author":[{"given":"Sangeetha","family":"Venugopal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.11.012_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","article-title":"WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature","volume":"19","author":"Elliott","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.012_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/jcp.56.4.292","article-title":"Evidence of clonality in chronic neutrophilic leukaemia","volume":"56","author":"B\u00f6hm","year":"2003","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clml.2018.11.012_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ajh.2830410424","article-title":"Chronic neutrophilic leukemia: case report documenting the absence of BCR-ABL rearrangement","volume":"41","author":"Storek","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.2830410110","article-title":"Elevated neutrophil function in chronic neutrophilic leukemia","volume":"41","author":"Ohtsuki","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood.V82.3.1035b.1035b","article-title":"Clonal nature of chronic neutrophilic leukemia [letter]","volume":"82","author":"Kwong","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajh.2830430416","article-title":"Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia","volume":"43","author":"Meyer","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib8","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-2141.1996.7082329.x","article-title":"Chronic neutrophil leukaemia in adolescence and young adulthood","volume":"94","author":"Hasle","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.11.012_bib9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-8652(199701)54:1<72::AID-AJH11>3.0.CO;2-C","article-title":"Deletion of the long arm of chromosome 20 in a patient with chronic neutrophilic leukemia: cytogenetic findings in chronic neutrophilic leukemia","volume":"54","author":"Matano","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1096-8652(199803)57:3<221::AID-AJH7>3.0.CO;2-X","article-title":"Neoplastic involvement of granulocytic lineage, not granulocytic-monocytic, monocytic, or erythrocytic lineage, in a patient with chronic neutrophilic leukemia case report","volume":"57","author":"Yanagisawa","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1999.01348.x","article-title":"Familial occurrence of chronic neutrophilic leukaemia","volume":"105","author":"Kojima","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.11.012_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1096-8652(200007)64:3<229::AID-AJH18>3.0.CO;2-9","article-title":"Chimeric del20q in a case of chronic neutrophilic leukemia","volume":"64","author":"Frank","year":"2000","journal-title":"Am J Hematol"},{"issue":"2 suppl","key":"10.1016\/j.clml.2018.11.012_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1067\/mjd.2001.103996","article-title":"Leukemia cutis in a patient with chronic neutrophilic leukemia","volume":"44","author":"Willard","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2018.11.012_bib14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/jcp.55.11.862","article-title":"Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease","volume":"55","author":"B\u00f6hm","year":"2002","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clml.2018.11.012_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2005.07.012","article-title":"Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined","volume":"19","author":"Elliott","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2018.11.012_bib16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.012_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4103\/0377-4929.85134","article-title":"Persistent neutrophilia progressing to polycythemia vera","volume":"54","author":"Singh","year":"2011","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.clml.2018.11.012_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","article-title":"ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia","volume":"90","author":"Elliott","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ajcp\/72.2.233","article-title":"Chronic neutrophilic leukemia. Report of two cases and review of the literature","volume":"72","author":"You","year":"1979","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2018.11.012_bib20","first-page":"210","article-title":"Chronic neutrophilic leukemia: a contemporary review","volume":"3","author":"Elliott","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.clml.2018.11.012_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12185-008-0128-x","article-title":"Bleeding tendency in chronic neutrophilic leukemia","volume":"88","author":"Shigekiyo","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00000441-192007000-00003","article-title":"A case of splenomegaly with polymorphonuclear neutrophil hyperleukocytosis","volume":"160","author":"Tuohy","year":"1920","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clml.2018.11.012_bib23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.012_bib24","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib25","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction)","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib26","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/cncr.10490","article-title":"Neutrophilic-chronic myeloid leukemia","volume":"94","author":"Verstovsek","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.11.012_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2141.2002.03234.x","article-title":"Chronic neutrophilic leukaemia: a distinct clinical entity?","volume":"116","author":"Reilly","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.11.012_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.leu.2401993","article-title":"Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study","volume":"15","author":"Elliott","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.012_bib29","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1080\/1042819021000016087","article-title":"Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia","volume":"43","author":"Piliotis","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.11.012_bib30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJM199508243330804","article-title":"Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia","volume":"333","author":"Dong","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.012_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.hoc.2012.10.002","article-title":"Granulocyte colony-stimulating factor receptor signaling: implications for G-CSF responses and leukemic progression in severe congenital neutropenia","volume":"27","author":"Touw","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2018.11.012_bib32","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1182\/blood-2012-01-406116","article-title":"Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia","volume":"119","author":"Beekman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib33","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1073\/pnas.91.11.4683","article-title":"Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases","volume":"91","author":"Corey","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2018.11.012_bib34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-14-3100","article-title":"The colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I","volume":"22","author":"Maxson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.11.012_bib35","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib36","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/leu.2016.376","article-title":"Enhanced MAPK signaling is essential for CSF3R induced leukemia","volume":"31","author":"Rohrabaugh","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.012_bib37","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.012_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-014-0077-1","article-title":"CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia","volume":"7","author":"Cui","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.11.012_bib39","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1046\/j.1432-1327.2001.02000.x","article-title":"Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET","volume":"268","author":"Minakuchi","year":"2002","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.clml.2018.11.012_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Crist\u00f3bal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat genet"},{"key":"10.1016\/j.clml.2018.11.012_bib42","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.012_bib43","doi-asserted-by":"crossref","first-page":"e0171608","DOI":"10.1371\/journal.pone.0171608","article-title":"Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis","volume":"12","author":"Shou","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.11.012_bib44","first-page":"28","article-title":"[The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia]","volume":"38","author":"Cui","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2018.11.012_bib45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What\u2019s different about atypical CML and chronic neutrophilic leukemia?","volume":"2015","author":"Dao","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2018.11.012_bib46","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12094-017-1722-2","article-title":"Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis","volume":"20","author":"Langabeer","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clml.2018.11.012_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","article-title":"Genomics of chronic neutrophilic leukemia","volume":"129","author":"Maxson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.012_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-018-0058-7","article-title":"CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival","volume":"8","author":"Szuber","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.11.012_bib51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2169\/internalmedicine.48.1334","article-title":"Chronic neutrophilic leukemia with congenital robertsonian translocation successfully treated with allogeneic bone marrow transplantation in a young man","volume":"48","author":"Goto","year":"2009","journal-title":"Int Med"},{"key":"10.1016\/j.clml.2018.11.012_bib52","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ajh.20805","article-title":"Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation","volume":"82","author":"Kako","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib53","first-page":"2383","article-title":"Chronic neutrophilic leukemia: a clinical perspective","volume":"8","author":"Menezes","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2018.11.012_bib54","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.2012.076901","article-title":"JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.012_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3343\/alm.2015.35.3.376","article-title":"T618I-mutated colony stimulating factor 3 receptor in chronic neutrophilic leukemia and chronic myelomonocytic leukemia patients who underwent allogeneic stem cell transplantation","volume":"35","author":"Lee","year":"2015","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.clml.2018.11.012_bib56","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/bmt.2014.35","article-title":"The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT","volume":"49","author":"Langabeer","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2018.11.012_bib57","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.012_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000345851","article-title":"Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alfa-2b","volume":"130","author":"Zhang","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2018.11.012_bib59","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.012_bib60","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I\u2013positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.clml.2018.11.012_bib61","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/leu.2014.39","article-title":"Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in\u00a0vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib","volume":"28","author":"Lasho","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.012_bib62","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00277-016-2664-4","article-title":"Clinical response to ruxolitinib in CSF3R T618\u2013mutated chronic neutrophilic leukemia","volume":"95","author":"Stahl","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib63","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00277-014-2272-0","article-title":"Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib","volume":"94","author":"Ammatuna","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.11.012_bib64","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.3324\/haematol.2016.163089","article-title":"Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib","volume":"102","author":"Nooruddin","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.012_bib65","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.3324\/haematol.2017.163790","article-title":"Ruxolitinib, a potent JAK1\/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia","volume":"102","author":"Gunawan","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.012_bib66","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1074\/jbc.273.6.3230","article-title":"Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor","volume":"273","author":"Corey","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.11.012_bib67","doi-asserted-by":"crossref","first-page":"99215","DOI":"10.18632\/oncotarget.22283","article-title":"MEK\/ERK addiction in CNL\/aCML","volume":"8","author":"Kesarwani","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.11.012_bib68","first-page":"e414","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna","year":"2015","journal-title":"Cureus"},{"key":"10.1016\/j.clml.2018.11.012_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19327","article-title":"Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling","volume":"537","author":"Dhawan","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.11.012_bib70","doi-asserted-by":"crossref","first-page":"e77818","DOI":"10.1371\/journal.pone.0077818","article-title":"Substrate and inhibitor specificity of the type II p21-activated kinase, PAK6","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018313703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018313703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:53Z","timestamp":1761870773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018313703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2152265018313703"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Neutrophilic Leukemia: Current and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}